(MLYS) Mineralys Therapeutics - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 2.345m USD | Total Return: 82.9% in 12m
Avg Turnover: 26.0M
Qual. Beats: 2
Qual. Beats: 0
Warnings
Share dilution 55.8% YoY
Altman Z'' -15.00 < 1.0 - financial distress zone
Extended 3d
Tailwinds
No distinct edge detected
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cardiorenal diseases caused by dysregulated aldosterone. Its lead product candidate, lorundrostat, is an oral aldosterone synthase inhibitor designed to address conditions including hypertension, chronic kidney disease, and obstructive sleep apnea. The company operates within the biotechnology sector, where high research and development costs are typical as firms navigate the multi-phase FDA approval process.
The business model centers on the proprietary development of targeted small molecules to meet unmet needs in the cardiovascular and renal markets. Unlike broad-spectrum antihypertensives, lorundrostat specifically targets the enzymatic production of aldosterone to manage metabolic drivers of high blood pressure. Investors should consult ValueRay to evaluate the companys clinical pipeline and market positioning. Formerly known as Catalys SC1, Inc., the firm was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
- Phase 3 trial results for lorundrostat impact clinical validation and market valuation
- FDA approval timeline for hypertension treatment dictates future commercial revenue potential
- Strategic partnerships or acquisition interest hinges on aldosterone synthase inhibitor efficacy
- R&D expenditure and cash runway determine the necessity for secondary equity offerings
- Competitive landscape in cardiorenal drug market influences long-term peak sales projections
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.21 > 0.02 and ΔFCF/TA 33.40 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.21 > 3% & CFO -136.4m > Net Income -151.8m |
| Net Debt/EBITDA: error (cannot be calculated) |
| Current Ratio: 44.33 > 1.5 & < 3 |
| Outstanding Shares: last quarter (82.8m) vs 12m ago 55.81% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.01%; Δ -0.01% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.98 (Total Current Assets 652.5m - Total Current Liabilities 14.7m) / Total Assets 652.9m |
| B: -0.76 (Retained Earnings -496.5m / Total Assets 652.9m) |
| C: -0.33 (EBIT TTM -167.3m / Avg Total Assets 503.9m) |
| D: -33.73 (Book Value of Equity -496.5m / Total Liabilities 14.7m) |
| Altman-Z'' = -33.72 = D |
As of May 24, 2026, the stock is trading at USD 30.23 with a total of 880,106 shares traded.
Over the past week, the price has changed by +9.02%,
over one month by +3.18%,
over three months by +3.18% and
over the past year by +82.90%.
Mineralys Therapeutics has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy MLYS.
- StrongBuy: 6
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 48.5 | 60.4% |
Revenue TTM = 0.0 USD
EBIT TTM = -167.3m USD
EBITDA TTM = -167.3m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 1.70b USD (2.35b + (null Debt) - CCE 646.1m)
Interest Coverage Ratio = unknown (Ebit TTM -167.3m / Interest Expense TTM 0.0)
EV/FCF = -12.46x (Enterprise Value 1.70b / FCF TTM -136.4m)
FCF Yield = -8.03% (FCF TTM -136.4m / Enterprise Value 1.70b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 50.0k) / Revenue TTM)
Tobins Q-Ratio = 2.60 (Enterprise Value 1.70b / Total Assets 652.9m)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = -132.2m (EBIT -167.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 44.33 (Total Current Assets 652.5m / Total Current Liabilities 14.7m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA -167.3m)
Debt / FCF = unknown (Net Debt none / FCF TTM -136.4m)
Total Stockholder Equity = 543.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -30.12% (Net Income -151.8m / Total Assets 652.9m)
RoE = -14.59% (Net Income TTM -151.8m / Total Stockholder Equity 1.04b)
RoCE = -26.22% (EBIT -167.3m / Capital Employed (Total Assets 652.9m - Current Liab 14.7m))
RoIC = -20.71% (negative operating profit) (NOPAT -132.2m / Invested Capital 638.1m)
WACC = 7.01% (E(2.35b)/V(2.35b) * Re(7.01%) + (debt-free company))
Discount Rate = 7.01% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 38.06%
[DCF] Fair Price = unknown (Cash Flow -136.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.38 | # QB: 2
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.54 | Chg30d=-14.76% | Revisions=-20% | Analysts=7
EPS next Quarter (2026-09-30): EPS=-0.56 | Chg30d=-11.52% | Revisions=-20% | Analysts=7
EPS current Year (2026-12-31): EPS=-2.18 | Chg30d=-4.20% | Revisions=-20% | GrowthEPS=+4.6% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-1.94 | Chg30d=-6.08% | Revisions=+20% | GrowthEPS=+11.1% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -20%